马来酸噻吗洛尔(Timolol Maleate) - 药物靶点：β-adrenoceptors_在研适应症：白内障，青光眼，开角型青光眼_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Timoiol Maleater、Timolol GS、Timolol maleate (JP17/USP)

+ [28]

靶点

β-adrenoceptors

作用方式

拮抗剂

作用机制

β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

眼部疾病肿瘤

在研适应症

白内障青光眼开角型青光眼+ [3]

非在研适应症-

原研机构

Bausch Health Americas, Inc.

在研机构

Sandoz, Inc.

Wakamoto Pharmaceutical Co., Ltd.Central Pharmaceutical JSC No. 3

+ [7]

非在研机构

Valeant Pharmaceuticals Australasia Pty Ltd.

上海奥科达医药科技股份有限公司Santen Oy

最高研发阶段批准上市

首次获批日期

美国 (1978-08-17),

开角型青光眼高眼压症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C17H28N4O7S

InChIKeyWLRMANUAADYWEA-NWASOUNVSA-N

CAS号26921-17-5

关联

55

项与马来酸噻吗洛尔相关的临床试验

NCT06813807

/ Completed临床1期

A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel Forming Solution After Multiple Dosing in Healthy Subjects with That of Timolol Maleate Gel in Subjects with Proliferating Superficial Infantile Hemangioma Who Have Completed the Study

The goal of this clinical trial is:
1)To evaluate the pharmacokinetic profiles and safety of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution in healthy adult subjects after multiple dosing; 2)To compare the systemic exposure (Cmax,ss and AUCss) of 0.5% Timolol Maleate Gel in subjects with proliferating superficial infantile hemangioma (completed) with that of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution in healthy adult subjects.
The main questions aim to answer are:
* Pharmacokinetic (PK) profiles of healthy adult subjects
* Safety Evaluation
* To compare the systemic exposure (Cmax,ss and AUCss) of 0.5% timolol maleate gel in subjects with proliferating superficial infantile hemangioma (completed) with that of 0.5% timolol maleate ophthalmic gel forming solution in healthy adult subjects.

开始日期2024-06-15

申办/合作机构

上海奥全生物医药科技有限公司

CTR20241787

/ Completed临床1期

一项马来酸噻吗洛尔眼用胶体溶液在健康受试者中多次用药后的药代动力学特征，与马来酸噻吗洛尔凝胶在增生期浅表型婴幼儿血管瘤受试者中已完成研究的药代动力学特征的对比研究

1）评价 0.5%马来酸噻吗洛尔眼用胶体溶液在健康成年受试者多次用药后的药代动力学（PK）特征及安全性； 2）比较 0.5%马来酸噻吗洛尔凝胶在增生期浅表型婴幼儿血管瘤受试者（已完成）与 0.5%马来酸噻吗洛尔眼用胶体溶液在健康成年受试者中的系统暴露（Cmax,ss和 AUCss）。

开始日期2024-06-15

申办/合作机构

上海奥科达医药科技股份有限公司

ChiCTR2400085459

/ Suspended临床1期IIT

A comparative study on the pharmacokinetic characteristics of timolol maleate ophthalmic colloidal solution after multiple administration in healthy subjects and the pharmacokinetic characteristics of timolol maleate gel in the patients with hyperplastic infant hemangioma with shallow phenotype

开始日期2024-06-14

申办/合作机构-

100 项与马来酸噻吗洛尔相关的临床结果

登录后查看更多信息

100 项与马来酸噻吗洛尔相关的转化医学

登录后查看更多信息

100 项与马来酸噻吗洛尔相关的专利（医药）

登录后查看更多信息

3,904

项与马来酸噻吗洛尔相关的文献（医药）

2025-05-01·MICROCHEMICAL JOURNAL

Simultaneous determination of brinzolamide, timolol maleate and its oxidative degradation product using univariate and multivariate green spectrophotometric methods

作者: Tantawy, Mahmoud A. ; Zaazaa, Hala E. ; Abd-ElSalam, Heba-Alla H. ; Nabil, Nada ; Mandour, Asmaa A. ; Naguib, Ibrahim A. ; Ibrahim, Mohamed A.

Spectrophotometric methods utilizing ratio-spectra were validated for simultaneous determination of Brinzolamide (BRZ) and Timolol maleate (TM) in the presence of the oxidative degradation product of TM (TM deg).TM deg interference was eliminated by dividing the zero-order absorption spectra of TM and BRZ by a concentration 20.00μg/mL of TM deg.The binary mixture was then analyzed via Method A which determined TM using a ratio difference spectrophotometric approach, where amplitude difference (ΔPA) of the TM spectra at 275.5 nm and 250.0 nm were used, as BRZ (ΔPA) was zero at these wavelengths.Method B involved adjusting the first derivative of the ratio spectra of BRZ and TM in order to determine BRZ selectively.When applying Δλ = 8, scaling factor = 10 and the maximum obtained at 243.8 nm, TM showed no contribution.Method C, involved dividing the total spectrum of the ternary mixture by a double divisor; the sum of the spectra of TM and TM deg.The amplitude of the first derivative of the resulting ratio spectra was measured at 243.7 nm to determine BRZ.Addnl., two multivariate methods, Partial Least Squares and Artificial Neural Networks were applied for determination of BRZ, TM and TM deg.Both models successfully determined BRZ, TM and TM deg.These methods were applied to analyze BRZ and TM in pharmaceutical formulations without matrix interference.Finally, the environmental sustainability of the proposed methods was evaluated.Two methods; National Environmental Methods Index and Eco-Scale assessment metric systems were utilized and revealed greenness of proposed methods.

2025-04-01·Drug Delivery and Translational Research

Chitosan/carbomer nanoparticles- laden in situ gel for improved ocular delivery of timolol: in vitro, in vivo, and ex vivo study

Article

作者: Kouchak, Maryam ; Farrahi, Fereydoun ; Darvish, Sarah ; Rahbar, Nadereh

Due to the small capacity of the eye cavity and the rapid drainage of liquid into the nasolacrimal duct, patients must frequently administer the drops. Nanoparticles (NPs) and in situ gel systems have each proven their ability to achieve eye retention independently. In this study, timolol-loaded chitosan-carbomer NPs were prepared using the polyelectrolyte complexation method, and incorporated into a pH-responsive in situ gel system made of carbomer. The rheological behavior of NPs-laden in situ gel was examined at room and physiological conditions. Characteristics such as zeta potential, surface tension, refractive index, mucoadhesive properties, drug release, transcorneal permeability, and intra-ocular pressure (IOP) lowering activity were investigated on NPS and NPs-laden in situ gel formulations. The optimum gained NPs system had an encapsulation efficiency of about 69% with a particle size of 196 nm. The zeta potential of the NP and NPs-laden in situ gel were - 16 and + 11 mV respectively. NPs-laden in situ gel presented enhanced viscosity at physiological pH. All physicochemical properties were acceptable for both formulations. NPs and NPs-laden in situ gel systems proved to sustain drug release. They showed mucoadhesive properties which were greater for NPs-laden in situ gel. IOP reduction by NPs-laden in situ gel was significantly higher and more long-lasting than the timolol solution and NPs. In conclusion, the developed NPs-laden in situ gel is a promising carrier for ocular drug delivery due to the slow release of drug from nanoparticles, its mucoadhesive properties, and high viscosity acquisition in contact with precorneal film, which lead to improved therapeutic efficacy.

2025-03-01·Ophthalmology Glaucoma

Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Article

作者: Bacharach, Jason ; Wirta, David L ; Tepedino, Michael E ; El-Harazi, Sherif M

PURPOSE:

Sepetaprost is a novel investigative prodrug, the active form of which is a dual agonist targeting both prostaglandin F receptors and prostaglandin E receptor 3. This study (NCT04742283) aimed to demonstrate the noninferiority of sepetaprost ophthalmic solution 0.002% to timolol maleate ophthalmic solution 0.5% in participants with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).

DESIGN:

A phase IIb, randomized, double-masked, active-controlled, multicenter study conducted in the United States.

PARTICIPANTS:

In total, 323 adult (≥18 years) participants (POAG, 68.4%; OHT, 31.6%) were randomized 1:1 to receive either once-daily sepetaprost (n = 162) or twice-daily timolol (n = 161) in 1 eye for 3 months.

METHODS:

Intraocular pressure (IOP) was measured at 3 timepoints (8:00 am, 10:00 am, and 4:00 pm) at 3 visits (weeks 2 and 6 and month 3).

MAIN OUTCOME MEASURES:

The primary efficacy endpoint was noninferiority of sepetaprost to timolol. Noninferiority was established if the upper limit of the 2-sided 95% confidence interval (CI) for the difference in mean IOP (sepetaprost minus timolol) was ≤1.5 mmHg at all 9 specified timepoints and ≤1.0 mmHg at 5 or more of the 9 timepoints. Superiority was tested if noninferiority was achieved. Safety, including adverse events (AEs) and suspected adverse reactions, was evaluated throughout.

RESULTS:

The primary endpoint, the noninferiority of sepetaprost to timolol in mean IOP reductions, was met. The upper limit of the 2-sided 95% CI for the between-group difference in mean IOP score was <1.0 mmHg at all 9 timepoints. Superiority of sepetaprost to timolol was observed at 4:00 pm in week 2, week 6, and month 3; IOP mean difference (standard error): -0.76 (0.302), -0.73 (0.328), and -0.95 (0.319), respectively (all P < 0.05). Overall, 23.6% of participants receiving sepetaprost and 21.3% receiving timolol experienced AEs. The most commonly reported ocular AE in both groups was conjunctival hyperemia (sepetaprost, 9.9%; timolol, 2.5%).

CONCLUSIONS:

Once-daily sepetaprost 0.002% was statistically noninferior to twice-daily timolol 0.5% for lowering IOP in participants with POAG or OHT. There were no unexpected safety concerns observed, and all AEs were mild or moderate in severity.

FINANCIAL DISCLOSURE(S):

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

58

项与马来酸噻吗洛尔相关的新闻（医药）

2025-04-15

·米内网

【瞩目】立方制药拿下4亿大品种首仿

精彩内容近日，立方制药申报的4类仿制药盐酸哌甲酯缓释片获批生产并视同过评，为国内首仿+首家过评。这是一款中枢神经兴奋剂，原研产品2023年在中国公立医疗机构终端的销售额超过4亿元。盐酸哌甲酯缓释片是一种中枢神经兴奋剂，主要用于治疗注意缺陷多动障碍。米内网数据显示，盐酸哌甲酯缓释片已被纳入国家医保乙类目录，近年来在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售额逐年上涨，2023年突破4亿元，2024上半年以约39%的增速继续增长。近年来中国公立医疗机构终端盐酸哌甲酯缓释片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局仿制药申报方面，立方制药的盐酸哌甲酯缓释片于近日顺利获批生产，拿下国内首仿+首家过评。目前暂无其他企业的产品以新注册分类报产，预计短时间内其厂家竞争格局不会发生变化。2025年以来，立方制药有3个品种获批生产并视同过评，为盐酸哌甲酯缓释片、盐酸丙美卡因滴眼液、帕利哌酮缓释片，其中盐酸哌甲酯缓释片为国内首仿+首家过评，盐酸丙美卡因滴眼液为国产第4家获批且首家视同过评，帕利哌酮缓释片为公司获批的首款精神安定药。目前立方制药还有6个品种以新注册分类申报上市/临床在审，包括加替沙星滴眼液（暂无企业过评或视同过评）、贝派度酸片（暂无首仿）、美阿沙坦钾片、洛索洛芬钠口服溶液、美沙拉秦肠溶片、马来酸噻吗洛尔滴眼液，涵盖心脑血管系统药物、神经系统药物、感觉系统药物等治疗领域。立方制药以新分类申报且在审的品种来源：米内网中国申报进度（MED）数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至4月15日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2025-04-07

·GBIHealth

14.18亿美元！礼来获Sangamo旗下AAV衣壳用于开发基因治疗药物

药械追踪No.1 / AZ/第一三共Enhertu欧盟适应证扩大至HR+/HER2低表达或超低表达乳腺癌2025年4月7日，阿斯利康和第一三共联合宣布，注射用德曲妥珠单抗（商品名：Enhertu/优赫得）已获欧盟委员会（EC）批准新适应证，单药用于既往接受过至少一次内分泌治疗且被认为不适合继续接受内分泌治疗的不可切除或转移性激素受体（HR）阳性、HER2低表达或HER2超低表达乳腺癌成人患者。此次获批使Enhertu在HR+/HER2低表达乳腺癌的治疗线提前，并将适用患者群体扩大至涵盖HER2超低表达患者。Enhertu是阿斯利康和第一三共合作开发和商业化的HER2靶向抗体偶联药物（ADC），已在全球多个市场获批用于HER2阳性乳腺癌、非小细胞肺癌（NSCLC）、胃或胃食管结合部腺癌（GC/GEJC）等实体瘤适应证。Enhertu本次获欧盟批准扩展适应证主要基于III期试验DESTINY-Breast06的积极结果，该研究证实，与化疗相比，Enhertu使疾病进展或死亡风险降低了38%，并显著改善了患者的无进展生存期（mPFS：13.2个月 vs 8.1个月）。->点击文末阅读原文，解锁完整双语新闻No.2 / 参天制药青光眼滴眼液Tapcom在华获批2025年4月4日，日本参天制药株式会社（以下简称“参天制药”）宣布，旗下Tapcom（他氟前列素/噻吗洛尔复合滴眼液，研发代号：STN1011101）已获中国国家药品监督管理局（NMPA）批准。Tapcom为不含防腐剂的固定复方滴眼液，含0.0015%他氟前列素和0.5%马来酸噻吗洛尔；这2种对房水动力学有不同作用机制的有效成份均能降低眼压。Tapcom适用于降低开角型青光眼或高眼压症患者的眼压，为局部使用β受体阻滞剂或前列腺素衍生物单药治疗未能达到目标眼压的患者提供新的治疗选择，同时也适用于长期局部使用青光眼药物期间可能受益于不含防腐剂滴眼液的患者。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / ABL Bio与GSK达成超20亿英镑合作，开发神经退行性疾病创新药物2025年4月6日，韩国临床阶段生物技术公司ABL Bio Inc.（KOSDAQ：298380）宣布与葛兰素史克（GSK）达成全球授权协议，授权GSK利用ABL Bio的血脑屏障（BBB）穿梭平台Grabody-B，开发治疗神经退行性疾病的创新药物。该协议针对包括抗体、多核苷酸或寡核苷酸（如siRNA和ASOs）在内的多种治疗模式，双方将合作开发针对全新靶点的多个项目，以满足神经退行性疾病患者尚未被满足的重大医疗需求。根据协议条款，ABL Bio将获得高达7710万英镑的预付款及近期款项，包括3850万英镑的即时预付款、研究里程碑付款及潜在项目扩展费用。基于多个潜在项目，ABL Bio总共将有资格获得高达20.75亿英镑的研究、开发、监管审批及商业化里程碑付款。若产品成功商业化，ABL Bio还将获得净销售额的分级特许权使用费。作为协议的一部分，ABL Bio将向GSK转让Grabody-B相关技术和专有技术，而GSK将负责临床前和临床开发、生产及商业化。->点击文末阅读原文，解锁完整双语新闻No.2 / 14.18亿美元！礼来获Sangamo旗下AAV衣壳用于开发基因治疗药物2025年4月3日，Sangamo Therapeutics（Nasdaq：SGMO）宣布，已与礼来（NYSE：LLY）达成许可协议，授予礼来公司Sangamo创新的专有嗜神经性腺相关病毒（AAV）衣壳STAC-BBB全球独家使用权，该衣壳已在非人类灵长类动物中显示出强大的血脑屏障穿透能力和神经元转导能力。根据协议，礼来可使用STAC-BBB衣壳用于一个初始靶点，并在支付额外的许可靶点费用后，有权增加多达四个额外靶点，以提供其静脉注射给药的基因治疗药物，用于治疗某些中枢神经系统疾病。Sangamo负责完成与STAC-BBB衣壳相关的技术转移。礼来公司负责所有研究、临床前和临床开发、监管互动、生产以及任何由此产生的基因治疗产品的全球商业化。Sangamo将从礼来公司获得1800万美元的前期许可费，并有资格在五个潜在神经疾病靶点上获得高达14亿美元的额外许可靶点费用和里程碑付款，以及按这些产品的潜在净销售额分层的特许权使用费，但需根据某些特定条款进行相应减免。->点击文末阅读原文，解锁完整双语新闻No.3 / 百济神州终止欧司珀利单抗肺癌潜在疗法临床开发项2025年4月3日，百济神州（Nasdaq：ONC；6160.HK；688235.SH）宣布，将终止抗TIGIT抗体欧司珀利单抗（BGB-A1217）作为肺癌潜在治疗方法的临床开发项目。依据预先计划的无效性分析结果，独立数据监查委员会建议终止正在进行的3期AdvanTIG-302试验（NCT04746924）。试验的总体有效性和安全性数据评估表明，该研究或难以达到总生存期主要终点。但同时，未发现新的安全信号。经慎重考虑，公司决定终止该试验。欧司珀利单抗是一款TIGIT单抗，2021年12月，诺华曾斥资28.95亿美元引进该药，但该交易于2023年7月终止。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ xujingou@baidu.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

引进/卖出临床3期寡核苷酸抗体药物偶联物siRNA

2025-04-07

·Pharmaceutical Technology

China’s NMPA authorises Santen’s glaucoma treatment application

The eyedrop is an option for those who are benefitting from preservative-free eye drops. Credit: Andrey Sayfutdinov/Shutterstock. China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen Pharmaceutical’s Tapcom to treat individuals with open-angle glaucoma or ocular hypertension. This fixed-combination eye drop comprising tafluprost 0.0015% and timolol 0.5% is designed to lower intraocular pressure (IOP) for individuals with this condition. Glaucoma damages the optic nerve and results in visual field loss. The eye drop offers a therapeutic alternative for individuals whose topical beta-blockers or prostaglandin derivatives monotherapies have not achieved target IOP. It is also an option for those who are benefitting from preservative-free eye drops in prolonged topical usage of glaucoma medication. Tapcom is the country’s first preservative-free ophthalmic combo formulation to include a first-line prostaglandin derivative. Its two active ingredients, tafluprost and timolol maleate, work through different mechanisms to reduce IOP. Tafluprost acid, the active metabolite of tafluprost, is a prostanoid FP receptor agonist that promotes aqueous humour outflow. A nonselective β-receptor inhibitor, timolol maleate, decreases the production of aqueous humour. Tapcom has gained approval in 40 countries and regions, including Asia and Europe. Santen Pharmaceutical chief medical officer Peter Sallstig stated: “Glaucoma remains the leading cause of irreversible blindness worldwide, deeply impacting the quality of life of many patients. “Therefore, Santen has prioritised glaucoma as a key therapeutic focus, dedicating ourselves to the development of treatments that meet patients’ needs and the delivery of high-quality ophthalmic drugs. The approval of Tapcom in China represents a significant milestone, offering new treatment options for Chinese glaucoma patients and advancing the field of glaucoma care.” In November 2024, the company and Arctic Vision signed a commercial partnership agreement for the ARVN001 suprachoroidal injectable suspension for uveitic macular oedema and other ocular conditions.

上市批准

100 项与马来酸噻吗洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00603	马来酸噻吗洛尔	S01ED01 C07AA06	DBSALT000989

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白内障	日本	Wakamoto Pharmaceutical Co., Ltd.	1999-09-17
青光眼	日本	Santen Pharmaceutical Co., Ltd.	1981-06-04
开角型青光眼	美国	Bausch & Lomb, Inc.	1978-08-17
高眼压症	美国	Bausch & Lomb, Inc.	1978-08-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血管瘤	申请上市	中国	上海奥全生物医药科技有限公司	2024-11-01
血管瘤	申请上市	中国	上海新亚药业闵行有限公司	2024-11-01
毛细血管瘤	临床3期	中国	上海奥全生物医药科技有限公司	2020-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2021	N/A	视盘小疣	-	Timolol TM 0.01%	壓憲衊窪衊構壓製鹹齋(壓窪願壓簾膚製積積繭) = 餘積憲衊鬱製遞繭積齋醖願襯製艱醖襯齋獵構 (壓獵範憲鏇蓋窪構願鏇 ) 更多	-	2021-06-01
NCT03323164 (CTgov)	临床4期	开角型青光眼 \| 低眼压性青光眼	35	Brimonidine Tartrate (Brimonidine)	壓鑰壓醖蓋鑰餘選願觸(選壓憲齋鏇顧顧顧網壓) = 餘繭衊願獵築襯齋衊蓋糧範糧觸淵觸餘衊願艱 (選淵鬱艱鹹選選壓夢願, 6.10) 更多	-	2020-12-31
				Timolol Maleate (Timolol)	壓鑰壓醖蓋鑰餘選願觸(選壓憲齋鏇顧顧顧網壓) = 窪簾獵築衊膚齋鹹壓窪糧範糧觸淵觸餘衊願艱 (選淵鬱艱鹹選選壓夢願, 6.47) 更多
LUNAR Study (ARVO2016)	临床3期	高眼压症 \| 开角型青光眼	387	Latanoprostene Bunod 0.024%	壓衊鹽襯艱憲醖憲築顧(觸夢鬱廠齋夢網廠窪夢) = 淵顧選廠襯鏇鹽壓獵顧鏇選鹽鏇選艱鏇製醖顧 (繭糧顧製艱壓糧糧窪構 ) 更多	积极	2016-05-01
				Timolol Maleate 0.5%	壓衊鹽襯艱憲醖憲築顧(觸夢鬱廠齋夢網廠窪夢) = 簾憲餘顧衊簾願憲齋窪鏇選鹽鏇選艱鏇製醖顧 (繭糧顧製艱壓糧糧窪構 ) 更多
ARVO2012	N/A	青光眼	-	Xalacom (Latanoprost+Timolol Maleate)	鏇壓鬱憲網鏇觸鏇選夢(憲夢鑰製顧鏇夢蓋艱餘) = 鏇獵艱憲積簾壓襯鑰窪膚夢醖鏇簾製構醖窪鬱 (壓鏇衊艱蓋範構選鹹選 ) 更多	-	2012-03-01
				Duotrav(Travoprost+Timolol Maleate)	鏇壓鬱憲網鏇觸鏇選夢(憲夢鑰製顧鏇夢蓋艱餘) = 獵壓簾壓獵製糧憲積願膚夢醖鏇簾製構醖窪鬱 (壓鏇衊艱蓋範構選鹹選 ) 更多
NCT00735449 (CTgov)	临床4期	青光眼	204	timolol maleate 0.5%+latanoprost 0.005%	鬱蓋鏇餘築糧膚顧餘簾(醖獵簾積鏇壓鹽鏇襯範) = 壓鬱壓獵窪遞獵選鹽襯憲蓋範鹽夢醖鹹衊糧構 (獵鏇願艱網觸膚構鬱艱, 2.46) 更多	-	2011-11-24
ARVO2008	N/A	-	-	Istalol	壓艱選獵積衊蓋夢製窪(糧積鹽廠餘鏇餘築蓋鏇) = 鹹餘鏇壓獵簾繭範製淵積遞願構壓鹽夢壓築遞 (選醖壓鬱窪糧製觸選夢 ) 更多	-	2008-05-01
				Betimol	壓艱選獵積衊蓋夢製窪(鏇鬱醖鹽繭糧積壓膚積) = 餘鬱構廠顧範醖鑰網醖廠醖鏇衊顧鏇艱醖顧蓋 (鏇積餘簾遞網艱鬱襯鑰 ) 更多
ARVO2007	N/A	近视	32	Topical Timolol Maleate	齋衊壓選鑰顧鹹繭蓋襯(鏇夢鑰膚簾積鑰醖襯積) = 衊構膚艱網築淵鏇鹽鏇糧膚積鑰廠願廠選夢遞 (膚窪齋鏇範襯齋夢顧網 )	-	2007-05-01
Pubmed \| Eur J Ophthalmol	N/A	高眼压症 \| 开角型青光眼	-	Timolol Maleate 0.5%	憲糧衊積膚艱獵願鹹襯(蓋憲艱憲壓遞繭壓淵艱) = 餘齋糧鏇鑰窪壓鹽製醖繭艱夢製窪鬱衊選齋餘 (積膚襯鏇窪膚膚糧膚鹽, +/ ~ 3.0) 更多	积极	2006-11-01
				Brinzolamide 1%	憲糧衊積膚艱獵願鹹襯(蓋憲艱憲壓遞繭壓淵艱) = 構鑰艱醖築獵選簾簾繭繭艱夢製窪鬱衊選齋餘 (積膚襯鏇窪膚膚糧膚鹽, +/ ~ 2.7) 更多
ARVO2006	N/A	高眼压症	-	Timolol Maleate 0.5%	憲齋憲繭醖網襯鏇齋簾(築憲艱獵膚獵蓋艱蓋築) = 衊範簾淵襯糧壓襯鹹網繭遞簾齋膚齋願簾觸選 (築遞網蓋獵鹹製窪淵鬱, 3.6)	积极	2006-05-01
				Brinzolamide 1%	憲齋憲繭醖網襯鏇齋簾(築憲艱獵膚獵蓋艱蓋築) = 廠憲鏇選鑰築鹹壓繭鹽繭遞簾齋膚齋願簾觸選 (築遞網蓋獵鹹製窪淵鬱, 3.3)
ARVO2002	N/A	-	11	0.5% Timolol Maleate with Preservative (0.005% Benzalkonium Chloride)	鏇膚簾夢鏇齋選壓鑰鹽(鬱範廠憲簾艱構範襯蓋) = 膚築製獵膚齋壓繭壓衊願蓋膚壓壓蓋艱壓窪鏇 (選淵艱獵壓顧醖蓋鑰蓋 ) 更多	-	2002-12-01
				0.5% Timolol Maleate without Preservative	鏇膚簾夢鏇齋選壓鑰鹽(鬱範廠憲簾艱構範襯蓋) = 範餘構膚壓糧鹹襯窪齋願蓋膚壓壓蓋艱壓窪鏇 (選淵艱獵壓顧醖蓋鑰蓋 ) 更多